

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Ublituximab for treating relapsing multiple sclerosis ID6350

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Neuraxpharm UK (ublituximab)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Brain and Spine FoundationBrain Charity	Board of Community Health Councils in Wales
MS-UK	British National Formulary
MARCHO LANCON LTD	_
Multiple Scierosis National Therapy Centres	The Court Committee of the Committee of the Court Cour
	Department of Health - Northern Ireland Health age Improvement Sections
Multiple Sclerosis Society Multiple Sclerosis Trust	Healthcare Improvement Scotland Health Technology Welse
Multiple Sclerosis Trust Navigala size I Allianas	Health Technology Wales
Neurological Alliance Neurological Alliance	Medicines and Healthcare products
• Shift.ms	Regulatory Agency
South Asian Health Foundation	Multiple Sclerosis Society Wales
Specialised Healthcare Alliance	National Association of Primary Care
	National Pharmacy Association
Healthcare professional groups	Neurological Alliance of Scotland
Association of British Neurologists	NHS Confederation
British Association of Neuroscience	Scottish Medicines Consortium
Nurses	Wales Neurological Alliance
British Geriatrics Society	Welsh Government
British Neuropathological Society	Welsh Health Specialised Services
British Society for Blood and Marrow	Committee
Transplantation and Cellular Therapy	
British Society of Physical and	Possible comparator companies
Rehabilitation Medicine	Novartis Pharmaceuticals UK Ltd
Chartered Society of Physiotherapy	(ofatumumab)
Institute of Neurology	Roche Products Limited (ocrelizumab)
London MS-AHSCT Collaborative	, ,
Group	Relevant research groups
National Neurosciences Advisory	Brain Research UK
Group	Cochrane Multiple Sclerosis and Rare
Primary Care and Community	Diseases of the Central Nervous
Neurology Society	System Group
Royal College of General Practitioners	Genomics England
Royal College of Nursing	MRC Clinical Trials Unit

Final stakeholder list for the evaluation of ublituximab for treating relapsing multiple sclerosis ID6350



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Occupational Therapists Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Therapists in MS 	 National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency
 UK Clinical Pharmacy Association UK Multiple Sclerosis Specialist Nurse Association Others	
Department of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Final stakeholder list for the evaluation of ublituximab for treating relapsing multiple sclerosis ID6350

Issue date: June 2024





Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.